Breaking News
Investing Pro 0
👀 Bezos, Buffett & Berkowitz: What's in Their Portfolios? Unlock Data

BioNTech Shares Slide After Q2 Revenue, EPS Miss

Published Aug 08, 2022 07:52
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters
 
22UAy
+1.63%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
PFE
-0.72%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Scott Kanowsky

Investing.com -- Shares in BioNTech SE (ETR:22UAy) slumped on Monday after the German medicine maker posted less-than-expected second quarter revenues and earnings despite backing its full-year guidance.

The Mainz-based group reported sales of €3.2 billion during the period and fully diluted earnings per share of €6.45. Analysts had expected revenue to come in at €4.01 billion with an EPS of €7.21. Weighing on these results was an agreement with the European Commission to delay deliveries of BioNTech's COVID-19 vaccine to September from June through August.

In May, Brussels said the move was designed to build up stocks of additional vaccines in time for campaigns to combat the spread of COVID-19 this autumn and winter.

"BioNTech believes the development of the pandemic remains dynamic, causing a re-phasing of orders and with this leading to fluctuations in quarterly revenues," the company said in a statement. BioNTech added it expects this volatility to continue for the rest of the fiscal year.

But the group reiterated its full-year outlook, with revenues expected at between €13 billion and €17 billion in 2022, thanks in part to demand for COVID vaccines.

Meanwhile, BioNTech and its U.S. peer Pfizer (NYSE:PFE) announced that they are planning to begin clinical trials of a new COVID jab for the BA.4 and BA.5 variants of Omicron. The shot still requires regulatory approval, but is expected to be available for delivery "as soon as October".

BioNTech Shares Slide After Q2 Revenue, EPS Miss
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email